Endo names new president, U.S. branded pharmaceuticals

DUBLIN — Endo International this week announced the appointment of Joseph Ciaffoni as president, U.S. branded pharmaceuticals, effective Aug. 15. Ciaffoni was most recently SVP global specialty medicines group for Biogen, where he led development and execution of global strategy for the company’s marketed and pipeline products. 

 

"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets,” Endo president and CEO Rajiv De Silva said. “His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business.”

 

Ciaffoni began at Biogen in 2012, and held various titles there, including SVP U.S. commercial. He has also previously served as EVP and  CFO of Shionogi and president of Shionogi Pharmaceuticals, as well as VP sales for Schering-Plough (now Merck). 

 

“I am thrilled to be joining Endo at a time of such significant opportunity for the business,” Ciaffoni said. “I look forward to leading Endo's U.S. branded pharmaceutical business, driving the development and execution of Endo's branded strategy and accelerating key growth drivers while, ultimately, helping improve patients' lives.”